Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 87,272 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 87,272 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the completion of the sale, the chief executive officer now directly owns 203,354 shares in the company, valued at approximately $29,160,963.60. This represents a 30.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Trading Up 5.6 %

Shares of NTRA traded up $7.39 during trading hours on Tuesday, hitting $140.02. 2,219,493 shares of the stock were exchanged, compared to its average volume of 1,336,563. The firm has a market capitalization of $18.93 billion, a P/E ratio of -79.56 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The business has a 50-day moving average of $165.10 and a 200-day moving average of $148.16.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in NTRA. Stephens Inc. AR acquired a new position in shares of Natera during the 3rd quarter valued at $258,000. QRG Capital Management Inc. bought a new stake in Natera in the third quarter valued at $671,000. Marks Group Wealth Management Inc acquired a new position in shares of Natera during the third quarter valued at about $206,000. M&G PLC boosted its position in shares of Natera by 3.0% during the 3rd quarter. M&G PLC now owns 104,302 shares of the medical research company's stock worth $13,246,000 after purchasing an additional 3,001 shares in the last quarter. Finally, Hanseatic Management Services Inc. grew its stake in shares of Natera by 23.6% in the 3rd quarter. Hanseatic Management Services Inc. now owns 891 shares of the medical research company's stock valued at $113,000 after buying an additional 170 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NTRA shares. Piper Sandler increased their price objective on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. BTIG Research reissued a "buy" rating on shares of Natera in a report on Friday, February 28th. The Goldman Sachs Group upped their target price on Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Finally, Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $173.56.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.